If, and I say IF, the new formulation proves to be a success and can be monetized, the constant bollocks being spewed here will cease post haste.
As with virtually every Biotech, whether well funded or not, it all hinges on the product being effective.
In case everyone hasn't realized as of yet, this space has, for some time now, reverted to the snail pace (for most that is) that it previously operated under, and by that I mean a ""rigid"" clinical process (again, for most, not all).
This means the wait could be long BUT very profitable IMO for those who held.
News 
Market Data 
Discover 
